Case Report Open Access
Volume 1 | Issue 3 | DOI: https://doi.org/10.46439/pediatrics.1.011
Antenatal SARS-COV-2 exposure leading to multisystem inflammatory syndrome (MIS-N) presenting with neonatal encephalopathy
Varnit Shanker1,2,*, Madhu Chaudhary3, Pooja Shanker4
- 1Department of Pediatrics and Neonatology, DACH Jaipur, India
- 2ALM Candidate, HES, Harvard University, USA
- 3Department of Pediatric Cardiology, Mahatma Gandhi Medical College and Hospital, Jaipur, India
Corresponding Author
Varnit Shanker, vas500@g.harvard.edu
Received Date: July 27, 2021
Accepted Date: September 08, 2021
Shanker V, Chaudhary M, Shanker P. Antenatal SARS-COV-2 exposure leading to multisystem inflammatory syndrome (MIS-N) presenting with neonatal encephalopathy. Clin Pediatr Neonatol. 2021; 1(3):41-44.
Copyright: © 2021 Shanker V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Antenatal SARS-COV-2 exposure leading to multisystem inflammatory syndrome (MIS-N) presenting with neonatal encephalopathy
A 22-day-old male neonate was admitted to the neonatal intensive care unit (NICU) with complaints of abnormal movements, fever, breath holding spells, refusal and bluish discoloration of skin. He was born at term with a birthweight of 2·72 kg to a mother with a history of positive polymerase chain reaction for SARS-Coronavirus-2 (SARS-COV-2) virus (RT-PCR-positive), asymptomatic 2019 novel coronavirus disease (COVID-19) at 32-33 weeks gestation, which did not require any supportive measures.
Cell therapies for neonatal encephalopathy: On the question of dose, route of administration, timing, and single versus multiple doses
The optimal range of cell dose, route of administration, and timing for the treatement of neonatal encephalopathy are not known. However, it is not practical to systematically interrogate all combinations of these variables in animal models to define the optimal cell therapy protocol. Despite this limitation, a number of trends are present in the literature that should be considered when designing future clinical and preclinical trials.
Multisystem inflammatory syndrome in children (MIS-C): The role of viral superantigens in COVID-19 disease
Superantigens are viral or bacterial virus proteins that can specifically activate a large ratio of T cells. In contrast to classic peptide antigen recognition, superantigens do not require processing in small peptides, but act as fully or partially processed proteins. They can bind to class II molecules of the main histocompatibility complex and stimulate T cells that express certain beta chains of the T cell recipient V.
Multisystem inflammatory syndrome in Adults (MIS-A)
SARS-CoV-2 virus is the cause of COVID-19 disease. This disease was initially thought to be a pure respiratory illness characterized by cough and fever however it soon became evident that it could cause kidney failure, strokes and involve multiple organ systems as the acute phase evolves into a cytokine storm 10-12 days after symptom onset [1] In April of 2020 reports from Europe [2] and United States highlighted MIS-C which occurs two to four weeks after the initial infection [3].
Incidence and outcomes of peripherally inserted central catheter associated thrombosis in a tertiary neonatal intensive care unit
Neonatal PICC and umbilical lines are common vascular access lines in the NICU. Venous thrombosis, phlebitis, local or systemic infections, and mechanical problems such as catheter leakage or breakage, occlusions, and incidental dislodgement are well documented complications of PICC lines.